Objective To investigate the association between M235T polymorphism of angiotensinogen (AGT) gene and cerebral infarction(CI) in Chinese.Methods AGT gene M235T polymorphism was examined in 75 cases with CI and 48 healthy controls by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP).Results The frequencies of AGT gene T235 allele and 235TT genetype were 0.78 and 0.64 respectively,compared with those of the control group (0.604 and 0.375 respectively ),the difference was significant(? 2=8.82, P

Objective To study the effect of lactobacillus on serum histamine ,interleukin‐5(IL‐5) ,interleukin‐12(IL‐12) and tissue intercellular cell adhesion molecule‐1(ICAM‐1) on the rats of allergic rhinitis model .Methods Totally 48 male SD rats were randomly divided into control group ,model group ,Lactobacillus (LBA) group (1 × 1010 CUF/kg) and loratadine (LRD) group (5 mg/kg) ,there were 12 SD rats in each group .LBA Group administered once daily for a total of 6 weeks ;LRD group administered once daily for seven days .Then the clinical symptoms indexes ,the content of serum histamine ,IL‐5 ,IL‐12 ,the changes of tissue pathological ,the mRNA and protein of ICAM‐1 were compared .Results Lactobacilli can significantly improve symptoms score of allergic rhinitis in rats ,the pathological score ,reduce serum histamine ,IL‐5 levels ,ICAM‐1 mRNA and protein expression of tissue , and increase IL‐12 proportion ,thus it showed significant efficacy .Conclusion Long‐term (approximately six weeks) given lactoba‐cilli played a therapeutic role of allergic rhinitis by reducing serum histamine ,IL‐5 levels and ICM A‐1 expression in tissues ,in‐creased serum IL‐12 level .

0.05). Radiographic analysis showed quite good results in 77 cases. Complications included delayed union in six cases, severe stiffness in one and neuropraxia in two. Conclusions Open reduction and internal fixation of intracondylar humeral fractures is a safe and effective technique. Meanwhile, triceps-split approach and olecranon osteotomy can obtain same clinical outcome for intracondylar humeral fractures.

Objective To investigate clinical results of shoulder hemiarthroplasty in treating comminuted proximal humeral fractures. Methods Shoulder hemiarthroplasty was performed from May 1997 to June 2004 in 28 cases with comminuted proximal humeral fractures who were followed up for mean 2.1 years. American Shoulder & Elbow Surgeon (ASES) score was adopted for evaluating pain after operation, range of active movement and function of daily work. Results Mean ASES score was 87.9(67-96 scores), with mean forward flexion of 132?, external rotation of 40?, mean VAS score of 2.6 and internal rotation at T_ 10 level. Strength and function of 23 cases reached 80% of the normal side six months postoperatively and 90% of the normal side one year postoperatively. Of all cases, 82% were satisfied with the treatment. Conclusion Only reconstruction of normal humeral length, tuberosity fixation and persevering rehabilitation can contribute to a successful result of hemiarthroplasty for the comminuted proximal humeral fractures.

OBJECTIVE:To explore the clinical efficacy and safety of cetuximab combined with NP regimen and radiotherapy in the treatment of advanced non-small cell lung cancer(NSCLC). METHODS:76 cases of advanced NSCLC were selected and randomly divided into control group and observation group according to different therapy methods,with 38 cases in each group. Control group received NP regimen(cisplatin 25 mg/m2+navelbine 12.5 mg/m2)+thoracic IMRT;observation group was additional-ly given cetuximab 400 mg/m2(first day),with maintenance dose of 250 mg/m2 weekly and last for 13 weeks. Short-term efficacy, survival situation were compared between 2 groups as well as the levels of T lymphocyte,Th1,Th2,immuneglobulin(Ig) and complement. The occurrence of ADR was recorded. RESULTS:The total effective rate of observation group was 86.84%,which was significantly higher than that of control group(65.79%),with statistical significance(P<0.05). Average survival period and 2-year survival rate of observation group were 18.70 months and 55.26%,which were significantly longer or higher than those of control group (14.75 months,31.58%),with statistical significance (P<0.05). The improvement rate of survival quality was 94.74% in observation group,which was significantly higher than 68.42% in control group,with statistical significance (P<0.05). After treatment,the levels of CD4+,CD4+/CD8+ and IgG were significantly increased in 2 groups,while the levels of CD8+, Th1,Th2 and Th1/Th2 were significantly decreased;the observation group was better than the control group,with statistical signifi-cance(P<0.05);there was no statistical significance in the levels of CD3+,IgA,IgM and complement 4 between 2 groups(P>0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS:Cetuximab combined with NP regimen and radiotherapy can improve clinical efficacy of advanced NSCLC,improve survival quality,prolong survival time and promote the recovery of Ig,complement and T lymphocyte,with good safety.

Aim The aim of the present study is to in-vestigate the effect of the specific antagonist NVP-AAM077 and Ro25-6981 of NMDA receptor subunit NR2A and NR2B on global cerebral ischemia-induced neuronal injury in the CA1 region. Methods Male C57BL/6 mice subjected to global ischemia by the three-vessel occlusion( 3-VO) method,were divided into four groups: sham-operated group,ischemia/reperfusion control group,NVP-AAM077 treatment group,and Ro25-6981 treatment group. Hippocampal sections were processed for Fluoro-Jade B staining to detect degenerating neurons and for Nissl staining to identify surviving neurons. The expression of brain derived neurotrophic factor( BDNF) were measured by Western blot. Results ① Transient brain ischemia induced selective and delayed neuron death in the CA1 region of the hippocampus at 12-minute ischemia after reperfusion 3 days. NR2A subtype specific antagonist NVP-AAM077 enhanced neuronal death after transient global ischemia ( P

CD46 is not only identified as a complement regulatory protein which protects host cells from complement attack, but also a new co-stimulatory molecule for human T cells. CD3/CD46 co-stimulation can induce a T-regulatory 1 cell (Tr1)-specific cytokine phenotype in human CD4(+) T cells. However, the role of CD46 as a co-stimulatory molecule in the modulation of the acquired immunity, such as transplant immunology, remains unclear. In this study, CD4(+) T cells were isolated from human CD46-transgenic C57BL/6 mice by magnetic-activated cell sorting, and further induced by anti-CD3, anti-CD28 and anti-CD46 antibodies respectively, and anti-CD3/anti-CD28 antibodies, anti-CD3/anti-CD46 antibodies, or the monoclonal antibody panel against CD3/CD28/CD46. The levels of interleukin-2 (IL-2), gamma-interferon (gamma-IFN), interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta) were detected in the supernatants of different groups. Suppression of allogeneic T cell proliferation were assessed by using mixed lymphocyte reaction (MLR) assay, in which monoclonal antibodies against CD46 were added to the culture. The results showed that CD3/CD28, CD3/CD46 and CD3/CD28/CD46 co-stimulation could significantly induce stronger proliferation of T cells than CD3 stimulation (P<0.05), and CD3/CD28/CD46 co-stimulation significantly increased the proliferation of T cells when compared with CD3/CD28 or CD3/CD46 co-stimulation (P<0.05 for each). IL-2 and gamma-IFN levels were much higher in CD3/CD28 co-stimulation group than in CD3, CD28, CD46 and CD3/CD46 groups (P<0.05 for each). IL-10 and TGF-beta levels were dramatically increased in CD3/CD46 co-stimulation group as compared with those in the CD3, CD28, CD46 and CD3/CD28 groups (P<0.05 for each). CD3/CD46 co-stimulation significantly inhibited the T cell proliferation and allogenic immune responses through the secretion of IL-10 and TGF-beta in MLR (P<0.05). These results suggested that CD3/CD46 can induce Tr1 cells to modulate allogenic immune responses, and it may become a novel target for the development of new therapeutic approach for T-cell-mediated diseases. CD46 plays an important role in regulating the T cell-mediated immune responses by bridging innate and acquired immunity.

Objective: To investigate the effect of nerve growth factor-β(NGF-β) on the proliferation and cell cycle of human pancreatic cancer MIA PaCa-2 cells. Methods: MIA PaCa-2 cells were treated with different concentrations of NGF-β and K252a (inhibitor of NGF-β receptor TrKA) alone or in combination. Clone forming rate, proliferation, and cell cycle of MIA PaCa-2 cells treated with different strategies were examined by clone formation assay, MTT, and flow cytometry, respectively. Results: NGF-β significantly increased the clone formation and proliferation of MIA PaCa-2 cells (P<0.05, P<0.01). K252a significantly inhibited the proliferation of MIA PaCa-2 cells (P<0.05), while NGF-β combined with K252a had no significant effect on the proliferation of MIA PaCa-2 cells. NGF-β arrested MIA PaCa-2 cell cycle in S phase, K252a arrested cell cycle in G_0/ G_1 phase, and NGF-β combined with K252a arrested cell cycle in S phase. Conclusion: NGF-β can enhance the proliferation of pancreatic carcinoma MIA PaCa-2 cells.

Objective To investigate the impact of simvastatin on blood lipid and the incidence of atrial fibrillation and ischemic-related events in patients with acute myocardial infarction accompanied by paroxysmal atrial fibrillation. Methods One hundred and three patients with acute myocardial infarction and paroxysmal atrial fibrillation were selected as subjects, and were divided into a simvastatin group and a control group. Forty-five patients were in the simvastatin group, who took simvastatin 20mg/d orally for 18 months; fifty-eight patients were in the control group, and received conventional therapy except for statins. All patients were followed up for 18months. The level of blood lipid, recurrence rate of paroxysmal atrial fibrillation, incidence rate of persistent or permanent atrial lipids did not change significantly in the control group (P＞0.05); concentrations of total cholesterol (TC) and low density lipoprotein five patients during 18 months follow-up in the simvastatin group (11.1%), whereas it occurred in 14 patients of the control group(24.1%, P＜0.05); the occurrence rate of persistent or permanent atrial fibrillation in the simvastatin group was 4.4%, which was lower than (6.6%), two rehospitalizations for deterioration of coronary heart diseases (4.4%), three cardiac deaths (6.6%), and one cerebral stroke (2.2%), which was lower evidently than in the control group (41.4%, P＜0.05). Conclusions Simvastatin can not only decrease the levels of serum TC and LDL-C but also prevent the occurrence of atrial fibrillation and ischemic-related events.

Based on the research of text (Ⅰ) which determined the fermentation medium, the fermentation condition of CNY086 including temperature, volume, inoculum and inoculum age had been studied by single factor and orthogonal experiment. The optimum temperature, liquid volume, inoculum and seed age were 15?C, 250 mL/500 mL, 15%, 10 h. Under the conditions above mentioned, enzyme activity reached 104.36 U/mL in 5 L fermentor.